These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36152730)

  • 21. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Smoots SG; Schreiber AR; Jackson MM; Bagby SM; Dominguez ATA; Dus ED; Binns CA; MacBeth M; Whitty PA; Diamond JR; Pitts TM
    Breast Cancer Res; 2024 Mar; 26(1):35. PubMed ID: 38429789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
    Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
    Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming.
    Jin J; Qiu S; Wang P; Liang X; Huang F; Wu H; Zhang B; Zhang W; Tian X; Xu R; Shi H; Wu X
    J Exp Clin Cancer Res; 2019 Aug; 38(1):377. PubMed ID: 31455352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
    Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
    Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
    J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer.
    Ali AI; Wang M; von Scheidt B; Dominguez PM; Harrison AJ; Tantalo DGM; Kang J; Oliver AJ; Chan JD; Du X; Bai Y; Lee B; Johnstone RW; Darcy PK; Kershaw MH; Slaney CY
    Clin Cancer Res; 2021 Nov; 27(22):6222-6234. PubMed ID: 34475103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zap-Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat.
    Troelsen KS; Calder EDD; Skwarska A; Sneddon D; Hammond EM; Conway SJ
    ChemMedChem; 2021 Dec; 16(24):3691-3700. PubMed ID: 34259396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.
    Yin C; Dai X; Huang X; Zhu W; Chen X; Zhou Q; Wang C; Zhao C; Zou P; Liang G; Rajamanickam V; Wang O; Zhang X; Cui R
    J Cell Mol Med; 2019 Mar; 23(3):2194-2206. PubMed ID: 30609207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
    Lemoine M; Derenzini E; Buglio D; Medeiros LJ; Davis RE; Zhang J; Ji Y; Younes A
    Blood; 2012 Apr; 119(17):4017-25. PubMed ID: 22408261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer.
    Tan X; Li Y; Hou Z; Zhang M; Li L; Wei J
    Exp Cell Res; 2023 Aug; 429(1):113647. PubMed ID: 37225011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma.
    Robinson RM; Basar AP; Reyes L; Duncan RM; Li H; Dolloff NG
    Cancer Chemother Pharmacol; 2022 May; 89(5):643-653. PubMed ID: 35381875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.